Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction.
Authors: Barton Ann Kristin, Shety Tarek, Bondzio Angelika, Einspanier Ralf, Gehlen Heidrun
Journal: BMC veterinary research
Summary
# Editorial Summary Recurrent airway obstruction (RAO) in horses involves destructive activity by matrix-metalloproteinases (MMPs) that overwhelms the protective effects of their natural inhibitors (TIMPs), ultimately driving irreversible lung fibrosis; monitoring the balance between these enzymes could help track disease progression and treatment response. Ten RAO-affected horses received 10 days of inhaled budesonide (1500 μg twice daily) combined with environmental dust reduction—including wood shaving bedding and wet hay—whilst researchers measured MMP-2, MMP-8, MMP-9 and TIMP-1 and TIMP-2 levels in bronchoalveolar lavage fluid using multiple analytical techniques (zymography, fluorimetry and species-specific ELISA). Clinical improvement and changes in BALF cytology correlated with altered metalloproteinase and inhibitor levels, confirming that MMP/TIMP ratios can serve as quantifiable biomarkers of treatment efficacy beyond traditional clinical assessment. For practitioners managing RAO cases, these findings suggest that biomarker profiling could provide objective evidence of whether a horse is responding to medical and environmental interventions, potentially guiding decisions about therapy adjustments or duration. The integration of inhaled corticosteroids with rigorous dust control appears to modulate the protease–antiprotease imbalance that characterises RAO, offering a mechanistic rationale for this combined therapeutic approach.
Read the full abstract on PubMed
Practical Takeaways
- •Combined approach of inhaled corticosteroid therapy (budesonide) plus environmental dust control (wood shaving bedding, wet hay) is effective for RAO management
- •Measuring MMP and TIMP levels in bronchoalveolar lavage fluid may help objectively assess treatment success beyond clinical observation alone
- •Environmental dust reduction is a critical component of RAO therapy—managing bedding and forage quality directly impacts airway inflammation markers
Key Findings
- •Inhalative budesonide (1500 μg BID) combined with environmental dust reduction improved clinical signs and BALF cytology in RAO horses over 10 days
- •MMP-2, MMP-9, and MMP-8 activity levels and MMP/TIMP ratios shifted favorably with treatment, indicating reduced tissue-damaging protease activity
- •Matrix metalloproteinase and TIMP levels correlate with clinical improvement and can serve as biomarkers for monitoring RAO treatment response